InscoBi "ApimezUS Converts to Public Before US Listing Application Disclosure... Approval Countdown"

InscoBi announced on the 30th that the listing application (S-1) for the U.S. securities market listing of its subsidiary Apimez's U.S. corporation (hereinafter ApimezUS) has been converted to public status, marking the countdown to listing approval.

InscoBi submitted the S-1 for ApimezUS's listing on the NYSE American U.S. securities market last January and has undergone about eight months of review and supplementation. With the documents now converted to public status, all procedures for approval have been completed, and listing approval is imminent. Currently, the S-1 listing application documents submitted by Apimez are publicly available and can be searched and verified on the Securities and Exchange Commission (SEC)'s electronic disclosure system, Edgar.

ApimezUS plans to begin full-scale fundraising for the Phase 3 clinical trial of Apitox's Multiple Sclerosis following its U.S. listing.

ApimezUS has also completed consultations with local U.S. clinical research organizations (CROs) for the clinical trial. All preparations have been made to commence the clinical trial. With the listing and successful fundraising, they aim to complete the Phase 3 trial in the shortest possible time.

ApimezUS plans to develop multiple pipelines using additional natural substances alongside the existing bee venom. They intend to expand new drug research and development (R&D) based on natural substances, moving from the current bee venom extract stage to recombinant protein drugs by recombining specific active ingredients. The company stated that preclinical studies for rheumatoid arthritis, lupus, and psoriasis have been completed, making it easier to expand indications after Phase 3.

An InscoBi official said, “By selecting a new lead underwriter and accelerating the listing process, we were able to advance the document public disclosure and listing approval procedures.” He added, “With the listing imminent, we will proceed smoothly with the Phase 3 clinical trial and fundraising, rapidly advancing not only Multiple Sclerosis but also related new drug manufacturing.”